麻豆666av-麻豆91精品-麻豆91精品视频-麻豆91精品一区二区-麻豆91精品一区二区不卡-麻豆91蜜臀

Sinopharm Capital, focusing on healthcare equity investments, was co-founded by the management team and Sinopharm Group in 2012. The management team consists of professional healthcare experts inside and outside of Sinopharm Group. As one of the earliest healthcare investment institutions in China, Sinopharm Capital has deep understandings of healthcare industrial trend/operation and capital management. We closely cooperate with Sinopharm Group to capitalize on our industry resources in sourcing and assessing investment opportunities, adding value to our portfolio companies as well.

Zhejiang Haibang Investment Management Co., Ltd. was founded in 2011. The company's "Haibang Talent Fund" is the first domestic venture capital fund with the theme of "returnee talent entrepreneurship", focusing on life and health, digital economy, new materials and high-end manufacturing in key areas. The company has accumulated 14 funds and a number of special funds with a management capital of nearly 4 billion yuan, and has invested in more than 90 companies, of which 14 companies have finished IPOs, mergers and acquisitions, and more than 10 companies are actively preparing for the IPO process. Among them, each project has a certain degree of industry benchmarking and industry guiding significance in the province.

HM Capital is a healthcare focused investment firm within the Hillhouse Capital Group's ecosystem. HM Capital is committed to building an investment platform with a global view and local execution to help early and growth-stage healthcare companies achieve accelerated development by leveraging the ecosystems of affiliated operating companies, the top-tier Asian private equity firm, and the premier international healthcare institution.

BOCOM Science and Technology Innovation Fund is China’s first bank-affiliated science and technology investment fund, with underlying investments aiming to be listed on the Science and Technology Innovation Board (STAR Market). The fund focuses on investing in artificial intelligence, new materials, bio-pharmaceuticals and next-generation information technology. The wholly-owned subsidiary of BOCOM International serves as fund manager, leveraging on the resources of the BOCOM Group to provide high-quality technology and innovation companies with full-scale comprehensive financial services.

Linden Asset Group (“LAG”) invests in revolutionary technologies, principally focusing on biotech and intelligent-tech. LAG aims to discover pioneers in the forefront of science from a long-term perspective, whose innovations would help ensure humanity lives in a healthier and happier way. With over 2 billion RMB in assets under management, LAG’s presence includes offices in China and Singapore. 

Panlin Capital, founded in 2010, is a limited partnership established under the laws of the PRC and is dedicated to ventures in the field of healthcare and intelligent technology, which primarily investing in tech startups at series pre-A and A rounds. Focusing on the theme of “Technological Innovation leads Consumption Upgrade”, we proactively deploy investments in innovative drugs & high-end medical devices as well as intelligence application & equipment.

In healthcare field，our Portfolio companies include Kangtai, Hybribio, Shenogen, Ribo, Apollomics, GenFleet, Passiontec, FortBio, Cothera, ABM, Virogin, KingstronBio, Antekang Checg, Thorough Images, LangRui, OSMUNDA ,etc.

Hidragon Capital is an independent research-driven private equity fund manager, built by a group of experienced investors. Hidragon Capital focused on the investment of sector leaders and innovators within the Pharma, Medical services, BioTech, MedTech and various sub-sectors. Our portfolio includes：Ascentage Pharma, Genfleet Therapeutics, Allist Pharmaceutical, YHLO Biotech, Epimab Biotherapeutics, Genchem, Zhuoyi Biology, ZYAK Biotech, Xihua Scientific, Kangsheng Medical Devices.

Shanghai Shanjin Asset Management Co., Ltd. (Shanjin Capital) was founded in 2016 . The current management scale exceeds 1 billion RMB.

As a private equity fund manager, the goal set by Shanjin Capital is to focus on core assets of China.  Also, Shanjin Capital's investment is in the purpose of assisting investors to get a substantial share in the new round of China economic transformation.

Our investment fields focus on Key & Core Technology and Healthcare. In the aspect of Key & Core Technology, we deeply involved in 5G, AI and semiconductor also their subdivision tracks. We have invested in Cloudwalk, United Winner(688518.SH), Q&C silicon (605183.SH), SNC New Energy Technology, CorEnergy, Suzhou Huntersun, and Bailian.AI.

In the aspect of Healthcare, we focus on the fields of biotech, medical instruments, and molecular diagnostics. Our portfolio includes excellent enterprises such as Suzhou Zelgen Biopharmaceuticals (688266.SH), TINAVI (688277.SH), SHIP Biological, Genfleet Pharmaceutical, and Shanxi Micot, etc.

In the future, Shanjin team will adhere to the path of value investment, conduct in-depth research focus on Key & Core Technology companies with high technical barriers. We earnestly hope to grow with outstanding companies together and create long-term value for investors and society together.

CSPC Pharmaceutical Group Co., Ltd. (CSPC) is a national-level innovative enterprise integrating R&D, production and sales of innovative drugs. The group’s total assets are 50 billion RMB, with 27000 employees. Hong Kong-Listed Company (01093.HK), among 100 billion market value club, is the component stock of HSI, and also the first pharmaceutical stock in the 50-year history of HSI. On March 22, 2019, CSPC Innovation (300765.SZ), a subsidiary of CSPC, successfully listed on the GEM, which realized the “Red Chip + A” financing pattern new era of the CSPC Group.

At present, there are more than 10 pharmaceutical production bases in Hebei, Shanxi, Shandong, Jiangsu, Jiangxi, Tianjin, and other provinces and cities. The products are sold in more than 100 countries and regions around the world, and 35 single varieties sold over 100 million RMB.

TF Capital focuses on investment in the life sciences industry, primarily investing in early-stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. Our investment team has vast experience and resources in industry to assist our portfolio companies.

Pu’en Guoxin Equity Investment Center (Limited Partnership) is jointly established by Guoxin Sichuang Investment Fund Management (Beijing) Co., Ltd., and a leading company in domestic pharmaceutical industry----CSPC (01093.HK), focusing on investing in innovative biotech company. Puen Guoxin aims to synergistically empower and enhance the value of invested projects through the combination of industrial capital and social capital, while creating income for investors and achieving a win-win situation for all parties.

Founded by senior experts in the field of medicine and healthcare, the core founding team is composed of scientist who have succeeded in starting a business in both US and China and senior manager of the world’s leading pharmaceutical companies. Team advantage complement, with valuable practical experience and resources in the pharmaceutical industry, and in-depth understanding of the latest medical research and development trends at home and abroad.

Lake Capital has long been focusing on investment opportunities in the field of healthcare, and has been deeply involved in the various sub-sectors and help potential businesses become leaders, help to introduce international leading products, technology to the Chinese market, providing more advanced and cost-effective medical products to the majority of medical professionals and patients in China.

The portfolio previously managed by the core team of Lake Capital cover innovative drugs, biosimilar drugs, and high-value-added medical devices and consumables, genetic immunotherapy and medical services.

South China Venture Capital (“SCVC”) is a professional asset management institution established in 2008 and with a focus on venture capital in the fields of biomedicine, semiconductor, artificial intelligence and other scientific and technological fields.

Suzhou Suxin Venture Capital Investment Co., Ltd is a sole subsidiary of Suzhou Trust Co., Ltd. Founded in Aug. 2^nd 2011, Suxin Venture Capital is a qualified PE company auththorized by Asset Management Association of China and China Banking and Insurance Regulatory Commission. As one of the early-founded PE found managers in Suzhou, Suxin Venture Capital has builded an expericenced and professional invest team. In the end of 2020, Suxin Venture Capital established Suxin Qikang Fund, which relis on Suzhou location and industry advantages and aims to invest outstanding medical companies.

Founded in 2013, Cherami Investment focuses on investment in life sciences and healthcare, new energy vehicles, and new materials/semiconductors. Cherami Investment is based in Guangzhou，in 2017,  Cherami Investment began to deploy overseas markets and cooperated with listed companies to develop medical business. Cherami has won the best science and technology investment institution and other awards in 2020. The current AUM exceeds RMB 8 billion, and the medical field focuses on innovative treatments and other emerging treatments. The investment scope covers Angel's round to C round. Past investment projects include: Tinavi, GreeNovo, PV Med, Gene Cradle, etc..

As a wholly owned subsidiary of Agricultural Bank of China Limited, ABC International Holdings Limited was incorporated in Hong Kong in November 2009. ABC International Holdings Limited has 8 wholly-owned subsidiaries, including ABCI Capital Limited, ABCI Investment Management Limited, ABCI Asset Management Limited, ABCI Securities Company Limited. ABCI provides integrated financial services in Hong Kong, including IPO sponsorship and underwriting, bond underwriting, financial advisory, asset management, direct investment, institutional sales, securities brokerage, securities advisory.

Dyee Capital focuses on investments in the modern service industry and gives priority to the fields of healthcare, information services and consumption upgrading. The management team has many years of investment, investment banking, and industry experience, and also has extensive market resources and professional post-investment service management. In the field of cancer treatment, Dyee Capital has invested in many innovative medical enterprises, including Zelgen Biopharmaceuticals (688266. SH), Allist Pharmaceuticals (688578. SH), Ionova Life Sciences, Elpiscience Biopharma, InventisBio, Maxinovel Pharmaceuticals, FutureGen Biopharm, Phanes Therapeutics, Yingli Pharma, Lead Biolabs and so on.

Qiaojing Capital focuses on the early investment in medical industry, especially in medical devices, biological diagnosis and medical services. In the field of medical devices, high-cost medical consumables are of great concern, such as Allgens Medical (688613), Cryofocus Medtech (Cryoablation of atrial fibrillation) and Venmed Tech (Peripheral vascular intervention). In the field of biological diagnosis, the growing of a series of well-known companies have been witnessed, such as Xiamen Spacegen (Precise diagnosis of tumors), Cygnus Biosciences (NGS Sequencing Platform) and Conlight Medical (Pharmacogenomics of psychiatric disorders). In the field of biomedicine, the layout of innovative biotech companies has been developed, such as Zhidao Biological Tech (Innovative drug discovery platform of protein), Jianxin Biomedical Tech (Drug discovery platform of bispecific antibody). In addition, Qiaojing Capital have invested a string of medical services companies with great potential, such as Orange Family Tech (Management of respiratory chronic diseases) and Zhixin Medical Supply Chain Management (Delivery of high-cost medical consumables). Based on clinical demands, Qiaojing Capital always adheres to the concept of value investment so as to cultivate innovative medical technologies and provide better solutions for health care.

Baidu Venture Capital is an independent venture capital institution initiated by Baidu Group, with a total of more than 700 million US dollars in the three phases of the US/RMB fund. Baidu Venture Capital focuses on the early pioneer companies of emerging technologies and commits itself on several major directions such as commercial consumption, medical care and people's livelihood, as well as technology extension. Relying on the strong support and resource sharing of Baidu Group, Baidu Venture Capital has formed a well-designed plan in the field of artificial intelligence. Currently, it has invested in new energy vehicles, life sciences, corporate services, smart cities, semiconductors, smart industries, and IoT life.

Shanghai Wenzhou investment management Co., Ltd. is a professional market-oriented investment institution with mixed ownership of state-owned assets. Focusing on the concept of "rooting industry and deeply cultivating medicine", the company focuses on investment in the field of biomedicine. Its core team has senior industry and investment background in the field of biomedicine. The company attaches great importance to the in-depth research of the industry, adheres to the steady and rational investment principle, and sincerely helps the development of the enterprise. 

Tailong Capital was established in 2021. It is a professional equity investment management institution focusing on biomedicine, medical equipment and general health fields, with a fund management scale of 20 billion yuan. It has a professional and experienced investment team, focusing on biomedicine, innovative medical devices, CXO core services and innovative fields, and outstanding biomedicine industry funds, and is committed to building a scientific and cross-cycle biomedicine industry. 

Asia Investment Capital is committed to responsible investing, which encourages environmental sustainability, social responsibility, and effective corporate governance. Our fund considers Environmental, Social and Governance (ESG) factors in internal operations and the investment process. We believe a sound ESG practice in our due diligence process and in the post- investment management of our portfolio companies contributes to long-term investment returns.

Huajin Capital was established in 1992. By realizing the coordinated development and mutual promotion of investment business, industrial operations, and science and technology parks, the company has successfully built a new development pattern of "equity investment management + entity industry operations + industrial innovation platform services".